Previous close | 1.3300 |
Open | 1.2000 |
Bid | 0.1500 |
Ask | 2.3000 |
Strike | 620.00 |
Expiry date | 2024-09-20 |
Day's range | 1.2000 - 1.2000 |
Contract range | N/A |
Volume | |
Open interest | 38 |
BOSTON, June 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland.
On June 3, 2024, Charles F. Wagner Jr., Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 3,250 shares of the company.
On May 31, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 4,600 shares of the company.